SCHEMBL3074145

SCHEMBL3074145

CCOC(=O)c1cc(CBr)cnc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.61
CYP4A11 Q02928 1/20 0.61
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CASP1 P29466 1/20 0.45
TSHR P16473 1/20 0.41
KMT2A Q03164 4/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 2/20 0.40
BAZ2B Q9UIF8 1/20 0.40
BAZ2A Q9UIF9 1/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.39
HSP90AA1 P07900 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8627488 0.89 CYP4F2 (0.50) CYP4F2CYP4A11ALDH1A1KDM4ECASP1
SCHEMBL31271554 0.85 CYP4F2 (0.45) CYP4F2CYP4A11ALDH1A1KDM4ETSHR
SCHEMBL23501075 0.84 CYP4F2 (0.55) CYP4F2CYP4A11ALDH1A1KDM4ETSHR
SCHEMBL29882204 0.84 CYP4F2 (0.55) CYP4F2CYP4A11ALDH1A1KDM4ETSHR
SCHEMBL21185677 0.82 CYP4F2 (0.54) CYP4F2CYP4A11ALDH1A1TSHRKMT2A
SCHEMBL29576319 0.82 CYP4F2 (0.54) CYP4F2CYP4A11ALDH1A1TSHRKMT2A
SCHEMBL2782609 0.82 OPRK1 (0.48) CYP4F2CYP4A11ALDH1A1KDM4ECASP1
SCHEMBL3983100 0.81 ALDH1A1 (0.49) CYP4F2CYP4A11ALDH1A1KDM4ECASP1
SCHEMBL3582809 0.81 CASP1 (0.49) CYP4F2CYP4A11ALDH1A1KDM4ECASP1
SCHEMBL4914393 0.81 CYP4F2 (0.40) CYP4F2CYP4A11ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-09 US disclosed
EP-2194045-A1 SUBSTITUTED PYRAZOLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2010-06-09 EP disclosed
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
EP-1824841-A1 SUBSTITUTED PYRROLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-08-29 EP disclosed
WO-2006064944-A1 SUBSTITUTED PYRROLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227846-A1 SUBSTITUTED PYRAZOLE DERIVATIVE AR, NR5A1, NR3C2 CYP4F2 581/4885CYP4A11 85/4885ALDH1A1 809/4885
US-20090270359-A1 SUBSTITUTED PYRAZOLE DERIVATIVES AR, NR5A1, NR3C2 CYP4F2 577/4885CYP4A11 84/4885ALDH1A1 816/4885
US-20080176906-A1 Substituted Pyrrole Derivative AR, NR5A1, MC2R CYP4F2 967/4885CYP4A11 92/4885ALDH1A1 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.